Cholestatic liver disease

Thursday 5th december
16.30 - 18.30 h.
Room D

Mirta Ciocca

Fernando Álvarez

627/197 EVALUATION OF THE EFFICACY AND SAFETY OF MARALIXIBAT IN PATIENTS WITH BILIARY ATRESIA AFTER HEPATOPORTOENTEROSTOMY: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (EMBARK)

627/342 BRAZILIAN ALAGILLE SYNDROME STUDY (BASS): RESULTS OF A MULTICENTER OBSERVATIONAL STUDY

627/48 NOVEL MUTATIONS IN FAMILIAL CHOLESTASIS-RELATED GENES BEYOND PFIC1-3 WITH VARIABLE PHENOTYPES AND OUTCOMES: RESULTS FROM A LARGE ARAB STUDY COHORT

Transforming Care in Biliary Atresia: From Pathogenesis to the Bedside

Jorge Abdon Bezerra

Biliary atresia in adolescence and adulthood: challenges on the road to transition

Kathleen Schwarz

Genetic liver disease: Is there a new diagnostic algorithm? Is it applicable worldwide?

Richard Thompson

Novel pharmacological therapies for neonatal cholestasis. Pros and Cons.

Huey-Ling Chen